A CD16a gene knockout NK cell and its preparation method and application

By using the sgRNA designed by the CRISPR/Cas system in human induced pluripotent stem cells, efficient knockout of the CD16a gene was achieved, and CD16a gene knockout NK cells were obtained for treatment and research, solving the technology in the research on ADCC mechanism Problem, providing effective tools for the treatment of autoimmune diseases.

CN116334082BActive Publication Date: 2024-11-26SHENZHEN GENOCURY BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310151282.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-15
Publication Date
2024-11-26
Estimated Expiration
2043-02-15

AI Technical Summary

Technical Problem

The research on ADCC mechanism in the prior art has not been completely solved, and there is a lack of effective regulatory research tools, especially in autoimmune diseases, there is insufficient knockout technology for CD16a gene.

Method used

A CRISPR/Cas system containing specific sgRNAs was designed to knock out the CD16a gene in human induced pluripotent stem cells and obtain CD16a knockout NK cells by differentiation for adjuvant therapy and research.

Benefits of technology

It realizes efficient cleavage of CD16a gene, destroys its open reading frame, and obtains the ideal CD16a gene knockout effect, providing an NK cell line for treatment and research, with simple operation, high repetition, and widely used in autoimmune diseases. Treatment and new drug creation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004090851960000061
    Figure BDA0004090851960000061
  • Figure HDA0004090851970000011
    Figure HDA0004090851970000011
  • Figure HDA0004090851970000012
    Figure HDA0004090851970000012
Patent Text Reader

Abstract

The present invention discloses a CD16a gene knockout NK cell and a preparation method and application thereof, and an sgRNA for knocking out the CD16a gene, the nucleotide sequence of which is shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. In the cell line of the present invention, efficient cutting occurs at the CD16a gene target site of the genome, the target site activity is high, and the CD16a open reading frame in the genome is effectively destroyed, achieving a very ideal effect. The method for preparing CD16a gene knockout NK cells of the present invention is simple to operate and has high repeatability. The prepared CD16a gene knockout NK cells can be widely used in the auxiliary treatment of autoimmune diseases, new drug creation and other aspects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of genetic engineering, and in particular relates to a CD16a gene knocked-out NK cell and a preparation method and application thereof. Background Art

[0002] ADCC, antibody-dependent cell-mediated cytotoxicity, refers to the binding of the Fab segment of an antibody to the antigenic epitope of a virus-infected cell or tumor cell, and the binding of its Fc segment to the Fc receptor on the surface of killer cells (NK cells, macrophages, etc.), mediating the direct killing of target cells by killer cells. Among them, NK cells are the main cells that can play the role of ADCC.

[0003] CD16a (FcγRIIIa) is an Fc receptor expressed on NK cells and involved in ADCC. It plays a key role in autoimmunity, and human autoantibodies binding to activated CD16a can trigger autoimmune diseases such as systemic lupus erythematosus.

[0004] However, the current research on ADCC mechanism is still incomplete, and the development of an effective regulatory research tool has become an urgent problem to be solved. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a sgRNA for knocking out the CD16a gene, which can be effectively used for knocking out the CD16a gene.

[0006] The present invention also provides an application of the above sgRNA.

[0007] The present invention also provides a method for knocking out the CD16a gene.

[0008] The present invention also provides a method for constructing CD16a gene knocked-out NK cells.

[0009] The present invention also provides a CD16a gene knockout NK cell constructed by the above method.

[0010] The present invention also provides the application of the above NK cells.

[0011] According to a first aspect of the present invention, a sgRNA for knocking out the CD16a gene is provided, and the nucleotide sequence of the sgRNA is shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

[0012] According to the second aspect of the present invention, an application of the above-mentioned sgRNA is proposed, and the application is an application in knocking out the cell CD16a gene.

[0013] In some embodiments of the invention, the cells include human induced pluripotent stem cells and NK cells.

[0014] According to the third aspect of the present invention, a method for knocking out the CD16a gene is proposed, the method comprising the following steps: introducing sgRNA and Cas protein into human induced pluripotent stem cells.

[0015] In some embodiments of the present invention, the mass ratio of the sgRNA and Cas protein added is 1:(1-3).

[0016] In some embodiments of the present invention, the sgRNA and Cas protein are added in a mass ratio of 1:2.

[0017] In some embodiments of the present invention, the Cas protein includes Cas9 protein, Cas12 protein or Cas13 protein.

[0018] In some embodiments of the present invention, the introduction is by electrotransfection or microinjection.

[0019] In some embodiments of the present invention, the electrotransfection condition is 450-500V electric shock once.

[0020] According to a fourth aspect of the present invention, a human induced pluripotent stem cell with CD16a gene knockout is provided, which is prepared by the above method.

[0021] According to a fifth aspect of the present invention, a method for constructing CD16a gene knockout NK cells is provided, the method comprising the following steps: adding CD16a gene knockout human induced pluripotent stem cells to NK differentiation medium I, culturing for 12-16 days, adding OP9-DL4 cells, and continuing to culture using NK differentiation medium II until NK cells are obtained;

[0022] The NK differentiation medium I is a medium obtained by adding cytokines BMP4, hVEGF, SB431542, Flt3, SCF and / or IL3 to the basic medium I;

[0023] In some embodiments of the present invention, the basal culture medium I comprises stemline II culture medium.

[0024] In some embodiments of the present invention, the concentration of BMP4 is 1-20 ng / mL.

[0025] In some embodiments of the present invention, the concentration of hVEGF is 10-100 ng / mL.

[0026] In some embodiments of the present invention, the concentration of SB431542 is 1-20 μM.

[0027] In some embodiments of the present invention, the concentration of Flt3 is 1-100 ng / mL.

[0028] In some embodiments of the present invention, the concentration of SCF is 1-100 ng / mL.

[0029] In some embodiments of the present invention, the concentration of IL3 is 1-100 ng / mL.

[0030] The NK differentiation medium II is a medium obtained by adding cytokines Flt3, IL-7, IL-15, IL-2, SCF and / or IL3 to the basic medium II.

[0031] In some embodiments of the present invention, the basic medium II includes MEMa medium and 8% to 12% FBS.

[0032] In some embodiments of the present invention, the concentration of Flt3 is 1-100 ng / mL.

[0033] In some embodiments of the present invention, the concentration of IL-7 is 1-100 ng / mL.

[0034] In some embodiments of the present invention, the concentration of IL-15 is 1-100 ng / mL.

[0035] In some embodiments of the present invention, the concentration of SCF is 1-100 ng / mL.

[0036] In some embodiments of the present invention, the concentration of IL3 is 1-100 ng / mL.

[0037] In some embodiments of the present invention, during the culture period using NK differentiation medium I, half of the medium is replaced every other day.

[0038] In some embodiments of the present invention, during the culture period using NK differentiation medium II, half of the medium is replaced every 2-3 days.

[0039] According to the sixth aspect of the present invention, a CD16a gene knockout NK cell constructed by the above method is proposed.

[0040] According to the seventh aspect of the present invention, an application of the above-mentioned CD16a gene knockout NK cells is proposed, and the application is an application in the preparation of a product for the treatment or auxiliary treatment of autoimmune diseases.

[0041] In some embodiments of the present invention, the autoimmune disease includes at least one of systemic lupus erythematosus, psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, Behcet's disease, Sjögren's syndrome, myasthenia gravis, celiac disease, type 1 diabetes, diffuse toxic goiter, Addison's disease, autoimmune vasculitis, pernicious anemia, dermatomyositis, polymyositis, and scleroderma.

[0042] In some embodiments of the present invention, the application is application in preparing ADCC mechanism research and regulation research tools.

[0043] According to some embodiments of the present invention, at least the following beneficial effects are achieved: First, the present invention uses human induced pluripotent stem cells, uses the CRISPR / Cas9 system to knock out genes in human induced pluripotent stem cells, and then differentiates the CD16a gene-knocked-out human induced pluripotent stem cells to obtain NK cells. In the cell line of the present invention, efficient cutting occurs at the CD16a gene target site of the genome, the target site activity is high, and the CD16a open reading frame in the genome is effectively destroyed, achieving a very ideal effect. The method for preparing CD16a gene-knocked-out NK cells of the present invention is simple to operate and highly repeatable. The prepared CD16a gene-knocked-out NK cells can be widely used in the auxiliary treatment of autoimmune diseases, new drug creation, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0045] Figure 1 This is a position diagram of the three sgRNA target sequences in Example 1 of the present invention in the CD16a gene sequence;

[0046] Figure 2 hiPSC-CD16a in Example 2 of the present invention + -1-4 (△8 / +5) cell sequencing sequence and wild type sequence alignment;

[0047] Figure 3 hiPSC-CD16a in Example 2 of the present invention + -2-2 (+1 / △4) cell sequencing sequence and wild type sequence alignment;

[0048] Figure 4 hiPSC-CD16a in Example 2 of the present invention +-3-24 (△2 / +7) cell sequencing sequence and wild type sequence alignment;

[0049] Figure 5 These are microscope images of the three CD16a knockout human induced pluripotent stem cell lines constructed in Example 2 of the present invention;

[0050] Figure 6 This is a graph showing the expression results of pluripotency genes of the three knockout cell lines in Example 2 of the present invention;

[0051] Figure 7 This is a flow cytometry result diagram of pluripotency gene expression of the three knockout cell lines in Example 2 of the present invention;

[0052] Figure 8 The karyotype analysis diagram of the three knockout cell lines in Example 2 of the present invention;

[0053] Fig. 9 For the flow cytometry detection of CD34 in Example 2 of the present invention + CD45 + Content test result diagram;

[0054] Fig.10 CD3 in Example 2 of the present invention - CD56 + Detection result diagram of

[0055] Fig.11 CD56 in Example 2 of the present invention + CD16 + Detection result diagram of

[0056] Fig.12 This is a graph showing the effect of NK cells' killing efficiency on target cells in the test example of the present invention. DETAILED DESCRIPTION

[0057] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0058] Example 1

[0059] According to the CD16a gene sequence in the Ensembl database (ENSPANG00000009890), sgRNA target prediction tool: https: / / portals.broadinstitute.org / gppx / crispick / public, thousands of target sequences were designed. The target sequences were verified by experiments, and the targets had no cleavage activity; or the cleavage activity was very low; or there was an off-target effect. Finally, three predicted target sequences were screened:

[0060] sgRNA1: AGGAAGACCCTATTCACCTGAGG (SEQ ID NO: 1);

[0061] sgRNA2: CTAGCTGCACCGGGTCACTGAGG (SEQ ID NO: 2);

[0062] sgRNA3:TCCTCCTTGAACACCCACCGAGG (SEQ ID NO: 3);

[0063] The positions of the three target sequences in the CD16a gene sequence are as follows: Figure 1 As shown, it was used to knock out the CD16a gene.

[0064] Example 2

[0065] This example constructs a CD16a gene knockout NK cell, and the specific method is as follows:

[0066] 1. Construction of human induced pluripotent stem cell line by electroporation of CRISPR-cas9

[0067] The sgRNA (sgRNA1, sgRNA2, sgRNA3) and cas9 protein (purchased from GenScript Biotech) artificially synthesized by GenScript Biotech were added at an amount of 200 pM; the amount of cas9 protein added was 100 pM, and the human induced pluripotent stem cell line was electrotransfected (480V, 0.5ms) after mixing. The electrotransfected human induced pluripotent stem cell line was cultured in E8 medium (Gibco, A15169 / A15171) for 120-240 hours (160 hours in this embodiment), monoclonal cells were selected, and the DNA of the monoclonal was extracted using a cell genomic DNA extraction kit (purchased from Tiangen), and sequencing was performed to screen the knocked-out CD16a human induced pluripotent stem cell line.

[0068] The sequencing results are as follows Figure 2-4 As shown in the figure, it can be seen that the three knockout cell lines (hiPSC-CD16a +-1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24 (△2 / +7)) both alleles mutated (increased / deleted), resulting in changes in the translated amino acids / proteins and even premature termination of translation, thereby causing CD16a to be unable to express normally. Therefore, it can be seen that the target sequence of the CD16a gene of the present invention has high cleavage activity, and the target sites shown in SEQ ID NO.1-3 in the cell line constructed by the present invention are selected for cleavage, and all can be efficiently cleaved. It shows that the target site of the present invention is reliable, and a knockout cell line can be obtained 100%, which can be used as an ideal target for CD16a gene knockout.

[0069] (1) Structural characterization of CD16a knockout human induced pluripotent stem cell lines

[0070] The 10x lens of the Ultra Optics BDS400 was used to screen the knockout CD16a human induced pluripotent stem cell line (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24(△2 / +7)) and wild-type human induced pluripotent stem cell line (hiPSC) were imaged by microscope. The imaging results are shown in Figure 5 As shown in the figure, it can be seen that microscopy imaging shows that the morphology of the knockout cell line is not significantly different from that of the wild type.

[0071] (2) Quantitative PCR detection of CD16a knockout human induced pluripotent stem cell lines

[0072] RNAprep pure cultured cell / bacterial total RNA extraction kit (DP430, purchased from Tiangenle) was used to extract the RNA of three knockout cell lines (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a +-3-24 (△2 / +7)) and control group hiPSC cells RNA, and then reverse transcribed using a reverse transcription reagent (Evo M-MLV Plus cDNA synthesis kit AG11615, purchased from Acry) to obtain cDNA, and then ChamQ SYBR qPCR MasterMix (Q311-02, purchased from Novazon) was used to perform qPCR detection of the expression levels of pluripotency genes (including OCT4, SOX2, NANOG, PAX6, SOX1, T, MIXL1, FOXA2, and SOX17 genes), with GAPDH gene as the internal reference. The primer sequences for qPCR detection are shown in Table 1, and the reaction procedure was carried out according to the instructions of the kit.

[0073] Table 1

[0074]

[0075] Test results such as Figure 6 As shown in the figure, it can be seen that the pluripotency genes of the three knockout cell lines are all expressed normally, and the specific expression genes of the mesendoderm are not expressed, proving that there is no differentiation into any germ layer.

[0076] (3) Flow cytometry detection of cell pluripotency gene expression

[0077] Three knockout cell lines (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24(△2 / +7)), and fluorescent staining of pluripotency genes OCT4, SSEA4, TTA-1-60, and TRA-1-81 was performed. The expression levels were detected using a Beckman Cytoflex S flow cytometer.

[0078] The flow cytometry results are shown in the figure Figure 7 As shown in the figure, it can be seen that the pluripotency genes of the three knockout cell lines are all expressed normally.

[0079] (4) Karyotype analysis

[0080] Three human induced pluripotent stem cell lines with CD16a knockout (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24 (△2 / +7)), and sent it to Shanghai Longtian Biotechnology Co., Ltd. for karyotype analysis. The results are as follows Figure 8As shown in the figure, it can be seen that the karyotypes of the three knockout cell lines are still normal.

[0081] 2. Differentiation of human induced pluripotent stem cell lines into HPC cells

[0082] The human induced pluripotent stem cell line with CD16a knockout (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24 (△2 / +7)) and control hiPSCs were induced to differentiate for 12-16 days by adding 2 mL of NK differentiation medium I (basal medium was stemline II (Sigma, S0192), and the basal medium also included 1-20 ng / mL BMP4 (10 ng / mL in this example), 10-100 ng / mL hVEGF (50 ng / mL in this example), 1-20 μM SB431542 (10 μM in this example), 1-100 ng / mL Flt3 (50 ng / mL in this example), 1-100 ng / mL SCF (50 ng / mL in this example), and 1-100 ng / mL IL3 (50 ng / mL in this example) for every 600,000 cells. The culture medium was half-changed every day, and the specific expression markers of HPC (CD34 + CD45 + ).

[0083] Flow cytometry detection of CD34 on day 16 of differentiation + CD45 + The test results are as follows Fig. 9 As shown in the figure, it can be seen that the three knockout cell lines can normally differentiate into HPC (CD34 + CD45 + )cell.

[0084] 3. Induce HPC cells to differentiate into NK cells

[0085] About 1 million HPC cells obtained in step 2 were transferred to about 150,000 OP9-DL4 cells, and 3 mL of NK differentiation medium II was added (basal medium was MEMa (Gibco, 32571-036) + 10% FBS (Gibco, 10091-148), and the basal medium also included Flt3 with a final concentration of 1-100 ng / mL (50 ng / mL in this example), IL-7 with a final concentration of 1-100 ng / mL (50 ng / mL in this example), L-15 with a final concentration of 1-100 ng / mL (50 ng / mL in this example), SCF with a final concentration of 1-100 ng / mL (50 ng / mL in this example), and IL-3 with a final concentration of 1-100 ng / mL (50 ng / mL in this example)) to induce differentiation for 14-16 days, during which half of the medium was changed every 2-3 days, and the NK cell-specific expression markers (CD3 + 、CD56 + ) and CD16.

[0086] Flow cytometry detection of CD34 on day 31 of differentiation + CD45 + The test results are as follows Figure 10-11 As shown in the figure, it can be seen that the three knockout cell lines (hiPSC-CD16a + -1-4(△8 / +5), hiPSC-CD16a + -2-2(+1 / △4) and hiPSC-CD16a + -3-24(△2 / +7)) can differentiate into NK cells normally, and the NK cells differentiated from the human induced pluripotent stem cell line with CD16a knockout cannot express CD16a normally.

[0087] Test Case

[0088] This test example verifies the ADCC effect of the CD16a gene knockout NK cells prepared in Example 2, and the steps are as follows:

[0089] NK cells (wild-type hiPSC cells and NK cells prepared in Example 2 with CD16a gene knockout using three sgRNAs) and target cells (Raji) were mixed at a ratio of 5:1, and killed for 4 h without adding anti-CD20 mab and with adding anti-CD20 mab at a final concentration of 10 nM, and the killing efficiency was detected.

[0090] The results are as follows Fig.12As shown in the figure, it can be seen that hiPSC-NK cells expressing CD16a promote the killing of Raji cells in the presence of anti-CD20 mab, while the killing ability of NK cells knocked out of CD16a is not affected by anti-CD20 mab. The results show that the present invention destroys ADCC mediated by NK cells through CD16a receptors by knocking out CD16a.

[0091] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A sgRNA for knocking out the CD16a gene, It is characterized in that The nucleotide sequence of the sgRNA is shown in SEQ ID NO: 1 or SEQ ID NO:

2.

2. Use of the sgRNA according to claim 1 in knocking out the CD16a gene in cells in vitro.

3. The use according to claim 2, It is characterized in that The cells include human induced pluripotent stem cells and NK cells.

4. A method for knocking out the CD16a gene, It is characterized in that The method comprises the following steps: introducing the sgRNA and Cas protein described in claim 1 into human induced pluripotent stem cells in vitro.

5. The method according to claim 4, It is characterized in that The introduction is by electrotransfection or microinjection; and / or, the Cas protein includes Cas9 protein, Cas12 protein or Cas13 protein.

6. A human induced pluripotent stem cell with CD16a gene knockout, It is characterized in that The CD16a gene knockout human induced pluripotent stem cells are prepared by the method according to claim 4 or 5.

7. A method for constructing CD16a gene knockout NK cells, It is characterized in that The method comprises the following steps: adding the CD16a gene knockout human induced pluripotent stem cells according to claim 6 to NK differentiation medium I, culturing for 12-16 days, adding OP9-DL4 cells, and continuing to culture using NK differentiation medium II until NK cells are obtained; The NK differentiation medium I is a medium obtained by adding cytokines BMP4, hVEGF, SB431542, Flt3, SCF and IL3 to the NK differentiation basal medium; The basal medium in the NK differentiation medium I is stemline II medium; The concentration of BMP4 is 1-20 ng / mL; The concentration of hVEGF is 10-100 ng / mL; The concentration of SB431542 is 1-20 μM; The concentration of Flt3 is 1-100 ng / mL; The concentration of SCF is 1-100 ng / mL; The concentration of IL3 is 1-100 ng / mL; The NK differentiation medium II is a medium obtained by adding cytokines Flt3, IL-7, IL-15, IL-2, SCF and IL3 to the NK differentiation basal medium; The basal medium in the NK differentiation medium II is MEMa medium and 8%-12% FBS; The concentration of Flt3 is 1-100 ng / mL; The concentration of IL-7 is 1-100 ng / mL; The concentration of SCF is 1-100 ng / mL; The concentration of IL3 is 1-100 ng / mL.

8. A CD16a gene knockout NK cell, It is characterized in that The method according to claim 7 is used to construct the